| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 公司是中国首批通过美国FDA的GLP检查，并同时具有AAALAC（国际实验动物福利审查认证协会）认证和中国CFDA、OECD（经济合作与发展组织）的GLP认证资质的药物临床前研究服务机构，是致力于为客户提供高质量和高效率的医药研发服务，帮助客户降低研发风险、节约研发经费，推进产品市场化进程的高新技术企业。作为从事医药研发外包服务的“合同研究组织”，主要为国内外药物研发机构和制药企业提供包括非临床安全性评价服务、药效学研究服务、动物药代动力学研究服务在内的药物临床前研究服务。 公司总部位于北京，下设五家子公司。截至2017年6月末，公司拥有640人的专业服务团队，已完成临床前研究专题超过6,300个，拥有逾2,000种药物的临床前研究经验，在国内临床前CRO企业中居于领先地位。 | ||||||||||||||||||||||||
| Main Business | 以药物非临床安全性评价服务为主的药物临床前研究服务和实验动物及附属产品的销售业务。 | ||||||||||||||||||||||||
| Legal Representative | 冯宇霞 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 高大鹏 | ||||||||||||||||||||||||
| Solicitors | 北京市康达律师事务所 | ||||||||||||||||||||||||
| Auditors | 瑞华会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 010-67869582 | ||||||||||||||||||||||||
| Fax No | 010-67869966-1077 | ||||||||||||||||||||||||
| Website | www.joinn-lab.com | ||||||||||||||||||||||||
| jiafengsong@joinn-lab.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 25/08/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 0.530 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.160 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 11.040 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 10.737B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |